Ocular Therapeutix (OCUL) Competitors $12.81 +0.04 (+0.31%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.80 -0.01 (-0.04%) As of 09/12/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, RNA, and CYTKShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Ocular Therapeutix (NASDAQ:OCUL) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do institutionals & insiders believe in OCUL or VRNA? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to OCUL or VRNA? In the previous week, Verona Pharma PLC American Depositary Share had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 11 mentions for Verona Pharma PLC American Depositary Share and 7 mentions for Ocular Therapeutix. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.74 beat Ocular Therapeutix's score of 1.31 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, OCUL or VRNA? Ocular Therapeutix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Do analysts recommend OCUL or VRNA? Ocular Therapeutix presently has a consensus target price of $17.20, suggesting a potential upside of 34.27%. Verona Pharma PLC American Depositary Share has a consensus target price of $109.00, suggesting a potential upside of 2.41%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma PLC American Depositary Share 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is OCUL or VRNA more profitable? Verona Pharma PLC American Depositary Share has a net margin of -36.62% compared to Ocular Therapeutix's net margin of -382.51%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Which has stronger valuation and earnings, OCUL or VRNA? Verona Pharma PLC American Depositary Share has lower revenue, but higher earnings than Ocular Therapeutix. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M34.98-$193.51M-$1.28-10.01Verona Pharma PLC American Depositary Share$42.28M216.96-$173.42M-$0.99-107.51 SummaryVerona Pharma PLC American Depositary Share beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.23B$2.54B$5.78B$10.18BDividend YieldN/A57.24%5.73%4.60%P/E Ratio-10.0123.6475.4626.02Price / Sales34.98545.33464.4091.13Price / CashN/A27.5625.8129.91Price / Book6.375.3812.166.25Net Income-$193.51M$32.95M$3.29B$270.76M7 Day Performance0.79%1.21%0.73%2.54%1 Month Performance1.51%5.08%4.41%5.73%1 Year Performance42.33%-1.67%62.61%25.85% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.9255 of 5 stars$12.81+0.3%$17.20+34.3%+42.3%$2.23B$63.72M-10.01230Positive NewsVRNAVerona Pharma PLC American Depositary Share2.31 of 5 stars$106.300.0%$109.00+2.5%+257.4%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.6217 of 5 stars$19.02+3.2%$17.33-8.9%+28.0%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences3.1404 of 5 stars$12.91-0.1%$16.38+26.8%+17.9%$8.82B$29.05M-18.44860Positive NewsRVMDRevolution Medicines4.1878 of 5 stars$41.06+1.4%$72.00+75.4%+6.5%$7.57B$11.58M-9.12250Trending NewsAnalyst ForecastAnalyst RevisionGRFSGrifols3.9808 of 5 stars$10.11-0.2%$10.30+1.9%+6.7%$6.96B$7.81B8.6423,822RYTMRhythm Pharmaceuticals3.2528 of 5 stars$99.77-2.3%$101.57+1.8%+93.9%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.1863 of 5 stars$34.62-4.0%$74.22+114.4%-34.2%$6.66B$627.24M-39.342,609Positive NewsABVXAbivax2.5649 of 5 stars$90.00+2.2%$92.33+2.6%+616.8%$6.65BN/A0.0061News CoveragePositive NewsEarnings ReportAnalyst ForecastShort Interest ↑RNAAvidity Biosciences2.1004 of 5 stars$48.05-4.6%$67.00+39.4%+7.3%$6.48B$10.73M-13.50190Trending NewsAnalyst ForecastGap UpCYTKCytokinetics4.3865 of 5 stars$52.09-1.7%$75.38+44.7%-8.5%$6.34B$18.47M-10.21250Positive News Related Companies and Tools Related Companies VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors GRFS Competitors RYTM Competitors LEGN Competitors ABVX Competitors RNA Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts